This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

NeoGenomics opposes US PTAB discretionary denial, citing public health concerns

By Melissa Ritti ( May 15, 2025, 18:51 GMT | Insight) -- A bid by Natera Inc. to short-circuit inter partes review of its oncologic testing patent should be denied, petitioner NeoGenomics Laboratories told the US Patent Trial and Appeal Board yesterday, because Natera’s enforcement efforts could jeopardize the health of cancer patients.NeoGenomics Laboratories is urging the US Patent and Trademark Office to turn down a request for a discretionary denial of its petition for inter partes review of a patented method for tracking the progression of certain head and neck cancers....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections